Author

Kai Yuan

China Pharmaceutical UniversityORCID 0000-0001-7239-449XUnclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Kai Yuan6 papers · Broad Institute

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

Dawei WangiD· 1 shared Fei HuangiD· 1 shared H Y Wang· 1 shared Haiping HaoiD· 1 shared Hanjun LiiD· 1 shared Jiayu DingiD· 1 shared Jinxin Jiang· 1 shared Junqi Cui· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Dawei WangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Piezo1 transduces mechanical signals to inhibit osteoclast fusion and coordinate bone homeostasis

Ying Wang, H Y Wang, Tianyou Kan, Junqi Cui, Xuran Li, Kai Yuan, Liao Wang, Mengning Yan, Linyang Chu, Hanjun Li, Z-F Yu

This study shows that Piezo1 transduces mechanical signals to inhibit osteoclast fusion and maintain bone homeostasis by activating a signaling pathway that suppresses osteoclast differentiation.

bioRxiv · Jun 6, 2026 · PreprintCell Biology

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

Wenbin Kuang, Jinxin Jiang, Xiao Wang, Dawei Wang, Minghui Ji, Yasheng Zhu, Kai Yuan, Jiayu Ding, Wenmu Wang, Mingge Song, Wenjian Min, Fei Huang, Liping Wang, Wanjian Gu, Haiping Hao, , Peng Yang

This study identifies PTPN2 as a therapeutic target in AML, discovers a selective inhibitor K73, and demonstrates its efficacy in reducing AML burden in vitro and in vivo.

bioRxiv · May 7, 2024 · PreprintCancer Biology